Novartis believes the price-setting provisions in the IRA are unconstitutional and will have long-lasting and devastating consequences for patients by limiting access to medicines now and in the future. We acceded to a “maximum fair price” for Entresto for 2026 only to avoid other untenable options including catastrophic fines or the removal of all our products from both Medicare and Medicaid. The price-setting process is not objective or transparent and does not reflect the true value of a medicine. Additionally, we believe that the price-setting provisions in the IRA will disincentivize innovation and limit our ability to discover and develop transformational new medicines for the people who need them most.
Entresto is a life-saving medicine with no therapeutic alternative that has helped more than 2 million US heart failure patients, and Novartis has always been committed to ensuring affordable access for patients. Today, 98% of Medicare beneficiaries taking Entresto can access their medicine with no prior authorization and pay on average $29 per month for Entresto. Price controls don’t mean patients will have better access or lower costs at the pharmacy counter.